Femasys Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
FEMY Nasdaq 3840 femasys.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Femasys Inc.

Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care - Sep 15th, 2026 7:00 am
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio - Sep 9th, 2026 7:00 am
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations - Aug 26th, 2026 7:00 am
Femasys Secures FDA Pathway for Non-Surgical Contraceptive - Aug 19th, 2026 11:36 am
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - Aug 19th, 2026 10:01 am
Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc - Aug 19th, 2026 8:37 am
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - Aug 19th, 2026 7:00 am
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update - Aug 14th, 2026 2:05 pm
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents - Aug 12th, 2026 7:00 am
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million - Aug 7th, 2026 7:25 am
Femasys Regains Compliance with Nasdaq Listing Requirements - Jun 24th, 2026 7:00 am
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More - May 29th, 2026 4:55 pm
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter - May 13th, 2026 7:00 am
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - May 8th, 2026 2:05 pm
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete - May 5th, 2026 7:00 am
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026 - Apr 22nd, 2026 7:00 am
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio - Apr 16th, 2026 7:00 am
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth - Apr 1st, 2026 7:00 am
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update - Mar 31st, 2026 2:05 pm
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - Mar 18th, 2026 7:00 am